Company Vinings Holdings Inc. Other OTC
Equities
NDYN
US92744A1051
Pharmaceuticals
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 27/10/22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 16/05/23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 27/10/22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 29/08/23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 27/10/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 27/10/22 | |
Director/Board Member | 55 | 27/10/22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 27/10/22 |
Gene Salkind
BRD | Director/Board Member | 70 | 27/10/22 |
Chris Calise
BRD | Director/Board Member | 51 | 27/10/22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 27/10/22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 27/10/22 |
Director/Board Member | 56 | 27/10/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,118,593 | 25,373,891 ( 68.36 %) | 0 | 68.36 % |
Company contact information
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSector
1st Jan change | Capi. | |
---|---|---|
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.64% | 167B |